Denmark-based UNION therapeutics A/S has appointed Kim Kjoeller as chief executive, effective 1 January 2021, and Günter Ditzinger as chief technology officer. The company, which focuses on infectious and inflammatory diseases, has expanded its clinical pipeline during 2020 from one to five late stage clinical candidates which include a psoriasis drug from LEO Pharma A/S. Dr Kjoeller is currently head of global research & development at LEO and will replace Rasmus Toft-Kehler, the current CEO and co-founder of the company.
Dr Ditzinger was most recently chief technology officer of Basilea Pharmaceutica Ltd and has also worked at Sanofi SA and Novartis.
UNION Therapeutics announced the appointments on 28 October 2020.
Copyright 2020 Evernow Publishing Ltd